Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Bronchogen

Ala-Asp-Glu-Leu Bronchial Tetrapeptide

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Evidence for Bronchogen (AEDL) rests entirely on preclinical rat models of obstructive lung pathology and organotypic tissue culture from Khavinson's St. Petersburg group (Kuzubova 2015, PMID 26468022; Titova 2017, PMID 30199201), with no Western randomized controlled trials and no independent replication of the reported bronchial-epithelium effects. Human use is limited to uncontrolled Russian clinical observation, so an honest grade is 1 (animal-only / traditional), a correction down from the current grade 2.

FDA
Not approved; never evaluated by FDA or EMA. Sold as a research chemical or an imported Russian supplement, not for human consumption in the US.
WADA
Not specifically named on the WADA Prohibited List; as a non-approved substance it could fall under S0 (non-approved substances) in competition.

Reference only. Not medical advice.

What can go wrong

No controlled human safety data; evidence is animal-only from a single Russian group, purity and identity of vendor material are unverified.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Bronchogen. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A Khavinson tetrapeptide bioregulator targeting bronchial epithelium, with Russian data on chronic respiratory conditions in aging.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Chronic respiratory conditions (Russian data)

How it is supposed to work

Bronchogen is a peptide bioregulator directed at the bronchial and respiratory system, promoted for lung support in the Khavinson framework, conceptually similar to Chonluten. Its tissue-specific mechanism is unproven in controlled human studies.

Bronchogen is a synthetic short peptide, a defined-sequence second-generation bioregulator aimed at bronchial tissue, a near-twin in purpose to Chonluten.

Type
Synthetic short peptide
Target
Bronchial tissue
Generation
Second (defined)
Use
Pulsed courses
Evidence
Preclinical and Russian
Western RCT
None

The Bronchial Label, A Near-Twin Of Chonluten

Bronchogen is effectively the bronchial-labeled counterpart to Chonluten, and it carries the identical situation. The mechanism is the family’s contested gene-regulation proposal, the respiratory claims are preclinical and Russian, and there are no independent human trials. The close overlap between Bronchogen and Chonluten is itself a useful illustration of how the system generates multiple near-identical organ labels on one shared, unreplicated evidence base.

Safety in detail

Human safety has not been established in any controlled trial. All efficacy signals are preclinical rat and tissue-culture findings from one research group and remain unreplicated, and marketed material is sold outside any regulatory approval.

  • Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
  • Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
  • Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
  • Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.

Children and teenagers

Bronchogen has no validated pediatric use and is an unapproved injected peptide. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Bronchogen reaches users only through the bioregulator gray market and longevity vendors, with no approved product.

How we got here

Bronchogen is one of the short synthetic peptide bioregulators (cytogens) designed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, modeled on peptide fractions the group first isolated from animal bronchial and lung tissue. The natural-extract precursor was later reduced to the defined synthetic tetrapeptide AEDL (Ala-Glu-Asp-Leu, coded AKS-B) and sold in Russia within the Cytogen supplement line by Peptide Bio / NPCRIZ, then re-exported internationally by Western vendors as a research-only lyophilized peptide. It sits alongside sibling Khavinson tetrapeptides such as Epithalon (pineal, AEDG), Vilon and Cortagen, which share the same developmental program and naming conventions, a closeness that produced the legacy mislabel `epitalon-peptamax` on this entry.

Bronchogen was developed as a defined-sequence organ bioregulator at the St. Petersburg institute, the bronchial-labeled member of the respiratory pair with Chonluten.

The numbers behind the grade

Type
Bronchial peptide
Target
Lungs / bronchi
Russia
Bioregulator line
FDA
Not approved
Evidence
Single-tradition
Western RCTs
None

The people taking it

A respiratory bioregulator within the Cytogen line, used by a small niche audience.

Bronchogen’s users are respiratory-health and longevity enthusiasts within the bioregulator-protocol community.

Used as a respiratory-support bioregulator within Russian-tradition protocols; not independently confirmed.

Set against the alternatives

Bronchogen is a near-twin of the lung peptide Chonluten, sharing the family’s framing applied to the airways. Its support is preclinical and single-lineage.

What we do not know

  • Whether independent, Western randomized trials confirm any of the claimed clinical effects.
  • Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
  • Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
  • Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.

Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Bronchogen.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Khavinson group studies2000s

    Reported respiratory-tissue effects within the bioregulator literature.

  • Independent replicationnone notable

    No independent Western trials of Bronchogen exist.